Literature DB >> 618577

A basis for fluoropyrimidine-induced antagonism to methotrexate in Ehrlich ascites tumor cells in vitro.

D Bowen, J C White, I D Goldman.   

Abstract

The inhibitory effect of methotrexate on [3H]deoxyuridine incorporation into DNA is reduced as the basal rate of this reaction is inhibited by pretreatment of Ehrlich ascites tumor cells with fluoropyrimidines. This observation is a basis for fluoropyrimidine-methotrexate antagonism in anticancer regimens and supports the concept that the sensitivity of thymidylate synthesis in tumor cells to methotrexate is related, in part, to the basal rate of thymidylate synthesis from deoxyuridylate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618577

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.

Authors:  R G Moran; M Mulkins; C Heidelberger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.

Authors:  J C Allegra; T M Woodcock; S P Richman; K I Bland; J L Wittliff
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

3.  5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.

Authors:  R Tausch-Treml; F Baumgart; D Ziessow; P Köpf-Maier
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil.

Authors:  L L Danhauser; R Heimer; E Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  The interaction between fluoropyrimidines and methotrexate, and [4C]-formate incorporation into nucleic acids and protein.

Authors:  D Bowen; E Fölsch; L A Guernsey
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 6.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.